Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
Neuhaus
P
P
Department of Surgery, UKRV, Freie Universitat Berlin, Germany.
Bechstein
W O
WO
Blumhardt
G
G
Steffen
R
R
Keck
H
H
Lemmens
P
P
Langrehr
J M
JM
Schlag
H
H
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016031:Liver Transplantation / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D016019:Survival Analysis; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D001379:Azathioprine; D011241:Prednisone